ANG Lifesciences India (BOM:540694) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540694 ANG Lifesciences India Ltd BOM:540694
63 GF Score
Price ₹35.80
GF Value ₹28.43
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is ANG Lifesciences India Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of ANG Lifesciences India is: High Risk: High uncertainty with risk-return tradeoff.

ANG Lifesciences India  (BOM:540694) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

ANG Lifesciences India Risk Assessment Related Terms

BOM:540694 vs ZTS: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ANG Lifesciences India Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's Risk Assessment distribution charts can be found below:

* The bar in red indicates where ANG Lifesciences India's Risk Assessment falls into.


BOM:540694
63GF Score
ANG Lifesciences India Ltd BOM:540694
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?

Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued. The current stock price of ₹35.80 is trading 25.9% above its estimated GF Value™ of ₹28.43. GuruFocus considers ANG Lifesciences India to be Modestly Overvalued.

Key valuation signals for BOM:540694:

  • Risk Assessment:
  • GF Value™: ₹28.43 vs. price of ₹35.80 (25.9% above fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANG Lifesciences India Business Description

Address Ranjit Avenue, B-Block, Darbara Complex, SCO 113, First Floor, District Shopping Complex, Amritsar, PB, IND, 143001
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
63GF Score

Get the complete analysis for BOM:540694

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹35.80
Price
₹28.43
GF Value